GoodRx Holdings Statistics
Total Valuation
GoodRx Holdings has a market cap or net worth of $1.78 billion. The enterprise value is $1.87 billion.
| Market Cap | 1.78B |
| Enterprise Value | 1.87B |
Important Dates
The next confirmed earnings date is Wednesday, May 7, 2025, after market close.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GoodRx Holdings has 383.61 million shares outstanding. The number of shares has decreased by -4.42% in one year.
| Current Share Class | 106.74M |
| Shares Outstanding | 383.61M |
| Shares Change (YoY) | -4.42% |
| Shares Change (QoQ) | -1.27% |
| Owned by Insiders (%) | 3.28% |
| Owned by Institutions (%) | 16.59% |
| Float | 90.86M |
Valuation Ratios
The trailing PE ratio is 115.75 and the forward PE ratio is 28.20. GoodRx Holdings's PEG ratio is 1.85.
| PE Ratio | 115.75 |
| Forward PE | 28.20 |
| PS Ratio | 2.25 |
| Forward PS | 2.11 |
| PB Ratio | 2.45 |
| P/TBV Ratio | 12.96 |
| P/FCF Ratio | 9.72 |
| P/OCF Ratio | 9.66 |
| PEG Ratio | 1.85 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.80, with an EV/FCF ratio of 10.24.
| EV / Earnings | 114.16 |
| EV / Sales | 2.36 |
| EV / EBITDA | 18.80 |
| EV / EBIT | 21.71 |
| EV / FCF | 10.24 |
Financial Position
The company has a current ratio of 5.32, with a Debt / Equity ratio of 0.75.
| Current Ratio | 5.32 |
| Quick Ratio | 5.10 |
| Debt / Equity | 0.75 |
| Debt / EBITDA | 5.05 |
| Debt / FCF | 2.97 |
| Interest Coverage | 1.63 |
Financial Efficiency
Return on equity (ROE) is 2.21% and return on invested capital (ROIC) is 3.93%.
| Return on Equity (ROE) | 2.21% |
| Return on Assets (ROA) | 3.62% |
| Return on Invested Capital (ROIC) | 3.93% |
| Return on Capital Employed (ROCE) | 6.82% |
| Revenue Per Employee | $1.07M |
| Profits Per Employee | $22,209 |
| Employee Count | 738 |
| Asset Turnover | 0.53 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GoodRx Holdings has paid $15.07 million in taxes.
| Income Tax | 15.07M |
| Effective Tax Rate | 47.90% |
Stock Price Statistics
The stock price has decreased by -35.88% in the last 52 weeks. The beta is 1.26, so GoodRx Holdings's price volatility has been higher than the market average.
| Beta (5Y) | 1.26 |
| 52-Week Price Change | -35.88% |
| 50-Day Moving Average | 4.61 |
| 200-Day Moving Average | 5.82 |
| Relative Strength Index (RSI) | 53.33 |
| Average Volume (20 Days) | 1,103,492 |
Short Selling Information
The latest short interest is 4.77 million, so 1.24% of the outstanding shares have been sold short.
| Short Interest | 4.77M |
| Short Previous Month | 5.05M |
| Short % of Shares Out | 1.24% |
| Short % of Float | 5.25% |
| Short Ratio (days to cover) | 3.09 |
Income Statement
In the last 12 months, GoodRx Holdings had revenue of $792.32 million and earned $16.39 million in profits. Earnings per share was $0.04.
| Revenue | 792.32M |
| Gross Profit | 744.11M |
| Operating Income | 86.20M |
| Pretax Income | -59.30M |
| Net Income | 16.39M |
| EBITDA | 99.54M |
| EBIT | 86.20M |
| Earnings Per Share (EPS) | $0.04 |
Balance Sheet
The company has $448.35 million in cash and $543.39 million in debt, giving a net cash position of -$95.04 million or -$0.25 per share.
| Cash & Cash Equivalents | 448.35M |
| Total Debt | 543.39M |
| Net Cash | -95.04M |
| Net Cash Per Share | -$0.25 |
| Equity (Book Value) | 724.66M |
| Book Value Per Share | 1.89 |
| Working Capital | 535.35M |
Cash Flow
In the last 12 months, operating cash flow was $183.89 million and capital expenditures -$1.24 million, giving a free cash flow of $182.65 million.
| Operating Cash Flow | 183.89M |
| Capital Expenditures | -1.24M |
| Free Cash Flow | 182.65M |
| FCF Per Share | $0.48 |
Margins
Gross margin is 93.91%, with operating and profit margins of 10.88% and 2.07%.
| Gross Margin | 93.91% |
| Operating Margin | 10.88% |
| Pretax Margin | 3.97% |
| Profit Margin | 2.07% |
| EBITDA Margin | 12.56% |
| EBIT Margin | 10.88% |
| FCF Margin | 23.05% |
Dividends & Yields
GoodRx Holdings does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 4.42% |
| Shareholder Yield | 4.42% |
| Earnings Yield | 0.92% |
| FCF Yield | 10.28% |
Analyst Forecast
The average price target for GoodRx Holdings is $8.39, which is 82.00% higher than the current price. The consensus rating is "Buy".
| Price Target | $8.39 |
| Price Target Difference | 82.00% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 6.45% |
| EPS Growth Forecast (5Y) | 88.77% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GoodRx Holdings has an Altman Z-Score of 2.16 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.16 |
| Piotroski F-Score | 7 |